Mogam Institute for Biomedical Research

Ki Joon Cho

Jae Hyun Park

Hyung-Kwon Lim

Mi Jung Lee

Mijung Lee

Dong-Sik Kim

Eun Jung Song

Jae Chan Park

Young Seoub Park

Kisu Kim

Ki Su Kim

Heechun Kwak

Sumin Lee

Kwan Yub Kang

SungHo Hwang

Eui Cheol Cho

Junhong Jeong

Sungho Hwang

An asymmetric fusion protein in which a fragment of an antibody binding to an insulin receptor, an iduronate-2-sulfatase (IDS) enzyme, and an Fc region are fused, and a use thereof are disclosed. The fusion protein can cross the blood-brain barrier (BBB) to deliver the IDS enzyme to the brain. Therefore, a pharmaceutical composition containing the fusion protein as an active ingredient can be used as a therapeutic agent for a central nervous system disease and particularly, is expected to prevent and treat various diseases caused by ribosome accumulation.

Fusion protein comprising IDS and use thereof

The present invention relates to an antibody that binds specifically to a tissue factor pathway inhibitor (TFPI), a nucleic acid encoding the antibody, a vector comprising the nucleic acid, a host cell transformed with the vector, a method for producing the antibody, and a pharmaceutical composition for treating hemophilia, which comprises the antibody as an active ingredient. The antibody of the present invention, which binds specifically to TFPI, can activate the extrinsic pathway of blood coagulation by inhibiting TFPI. Thus, the antibody of the present invention can be effectively used for the treatment of antibody-induced hemophilia patients and for the prevention of blood coagulation disease in hemophilia-A or hemophilia-B patients.

Antibody binding to TFPI and composition comprising the same

Growing community of inventors

Yongin-si, South Korea

Ki Joon Cho